Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
- PMID: 34870138
- PMCID: PMC8626571
- DOI: 10.1016/j.metop.2021.100149
Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
Erratum in
-
Erratum regarding previously published articles.Metabol Open. 2023 Jan 21;17:100231. doi: 10.1016/j.metop.2023.100231. eCollection 2023 Mar. Metabol Open. 2023. PMID: 36992679 Free PMC article.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a multifactorial metabolic disorder that was first described in 1980. It has been prevalent and on the rise for many years and is associated with other metabolic disorders such as obesity and type 2 diabetes mellitus (T2DM). NAFLD can be best described as a metabolic dysfunction that stems from insulin resistance-induced hepatic lipogenesis. This lipogenesis increases oxidative stress and hepatic inflammation and is often potentiated by genetic and gut microbiome dysfunction. As NAFLD progresses from simple steatosis to non-alcoholic steatohepatitis (NASH) and to cirrhosis and hepatocellular carcinoma (HCC), the odds of complications including cardiovascular disease (CVD), chronic kidney disease (CKD), and overall mortality increase. The aim of this review is to describe the metabolic causes and consequences of NAFLD while examining the risks that each stage of NAFLD poses. In this review, the etiology of "lean" NAFLD, the impact of obesity, T2DM, genetics, and microbiome dysbiosis on NAFLD progression are all explored. This review will also discuss the core issue behind the progression of NAFLD: insulin resistance (IR). Upon describing the causes and consequences of NAFLD, the effectiveness of diet modification, lifestyle changes, and glucagon-like peptide 1 receptor (GLP-1) agonists to retard NAFLD progression and stem the rate of complications is examined.
© 2021 Northwell Health.
Figures

Similar articles
-
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.Curr Diab Rep. 2020 Oct 5;20(11):59. doi: 10.1007/s11892-020-01349-1. Curr Diab Rep. 2020. PMID: 33015726 Review.
-
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103. World J Gastroenterol. 2015. PMID: 25892859 Free PMC article. Review.
-
Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).J Clin Exp Hepatol. 2023 Mar-Apr;13(2):273-302. doi: 10.1016/j.jceh.2022.11.014. Epub 2022 Dec 7. J Clin Exp Hepatol. 2023. PMID: 36950481 Free PMC article. Review.
-
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!Metabolism. 2019 Dec;101:154001. doi: 10.1016/j.metabol.2019.154001. Epub 2019 Oct 28. Metabolism. 2019. PMID: 31672448 Review.
-
Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).Adv Exp Med Biol. 2021;1261:223-229. doi: 10.1007/978-981-15-7360-6_20. Adv Exp Med Biol. 2021. PMID: 33783745
Cited by
-
Bridging the Gap: Exploring the Preclinical Potential of Pereskia grandifolia in Metabolic-Associated Fatty Liver Disease.Evid Based Complement Alternat Med. 2023 Nov 9;2023:8840427. doi: 10.1155/2023/8840427. eCollection 2023. Evid Based Complement Alternat Med. 2023. PMID: 38026733 Free PMC article.
-
Antidiabetic Properties of Chitosan and Its Derivatives.Mar Drugs. 2022 Dec 17;20(12):784. doi: 10.3390/md20120784. Mar Drugs. 2022. PMID: 36547931 Free PMC article. Review.
-
Assessing Trends in Hospitalizations for Breast Cancer among Women in Korea: A Utilization of the Korea National Hospital Discharge In-depth Injury Survey (2006-2020).J Epidemiol Glob Health. 2024 Jun;14(2):411-419. doi: 10.1007/s44197-024-00229-1. Epub 2024 Apr 29. J Epidemiol Glob Health. 2024. PMID: 38683484 Free PMC article.
-
Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study.Medicina (Kaunas). 2023 Nov 1;59(11):1935. doi: 10.3390/medicina59111935. Medicina (Kaunas). 2023. PMID: 38003983 Free PMC article.
-
Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications.Pharmacol Ther. 2023 Apr;244:108372. doi: 10.1016/j.pharmthera.2023.108372. Epub 2023 Mar 7. Pharmacol Ther. 2023. PMID: 36894027 Free PMC article. Review.
References
-
- Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434–438. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials